Oral Testosterone for the Treatment of Hypogonadism

TesoRx Pharma

Status and phase: Completed; Phase 2

Conditions: Hypogonadism

Treatments: Drug: TSX-002

Study type: Interventional

Funder types: Industry

Identifiers

NCT01717768

TT-002

Details and patient eligibility

About

Low testosterone is a condition that occurs when the body is unable to produce sufficient quantities of testosterone. The medical name for low testosterone is hypogonadism. Hypogonadism can be caused by many factors. Symptoms include: decrease in libido, lack of energy and mood swings. The goal of testosterone replacement therapy is to return testosterone levels to the normal range and relieve symptoms.

The purpose of this study is to evaluate the ability of TSX-002, which is testosterone provided in easy to swallow capsules, to maintain serum (blood) testosterone levels within the normal range in hypogonadal men. This will be determined by blood sampling at specified times during the study. The study is also intended to evaluate the tolerability of TSX-002, which will be taken orally twice per day for 15 days. In addition, the study is intended to determine a dosing regimen(s) that achieves testosterone levels within the normal range. Related Outcome Measures will be reported for Parts 1, 2, and 4.

A portion of the study (Part 3) to also assess the effect of a high-calorie, high-fat meal on the single dose pharmacokinetic exposure of TSX-002. Related outcome measures to be reported for Part 3.

Enrollment: 130 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prior documentation of a diagnosis of hypogonadism as evidenced by a screening serum testosterone < 300 ng/dL (based on the average of 2 morning samples taken at least 1 week apart)
• Men over the age of 18 years with a body mass index (BMI) < 39.0 kg/m2 and weighing ≥ 55 kg
• Hemoglobin levels at screening and baseline > 12.5 g/dL
• Testosterone treatment not contraindicated
• No evidence of suspected reversible hypogonadism
• Willing to abstain from current treatment for hypogonadism in accordance with approved labeling to facilitate an appropriate washout period before study participation (for nondepot formulations of testosterone only)
• Understands the requirements of the study and voluntarily consents to participate in the study

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

130 participants in 10 patient groups

Part 1: 120 mg BID

Experimental group

Description:

Oral TSX-002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days

Treatment:

Drug: TSX-002

Part 1: 240 mg BID

Experimental group

Description:

Oral TSX-002 240 mg BID (total dose = 480 mg/day) for a duration of 15 days

Treatment:

Drug: TSX-002

Part 2: 120 mg BID

Experimental group

Description:

Single cohort, open-label, nonrandomized oral TSX 002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days

Treatment:

Drug: TSX-002

Part 3: A-B-C 120 mg QD

Experimental group

Description:

Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C. * Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing. * Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing. * Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.

Treatment:

Drug: TSX-002

Part 3: B-C-A 120 mg QD

Experimental group

Description:

Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C. * Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing. * Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing. * Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.

Treatment:

Drug: TSX-002

Part 3: C-A-B 120 mg QD

Experimental group

Description:

Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C. * Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing. * Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing. * Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.

Treatment:

Drug: TSX-002

Part 4 Cohort 1: 60 mg BID/ 60 mg TID

Experimental group

Description:

Oral TSX-002 60 mg BID for 15 days then 60 mg TID for 15 days

Treatment:

Drug: TSX-002

Part 4 Cohort 2: 90 mg BID/ 90 mg TID

Experimental group

Description:

Oral TSX-002 90 mg BID for 15 days then 90 mg TID for 15 days

Treatment:

Drug: TSX-002

Part 4 Cohort 3: 180 mg QD

Experimental group

Description:

Oral TSX-002 180 mg once daily (QD) for 15 days

Treatment:

Drug: TSX-002

Part 4 Cohort 4: 120 mg BID

Experimental group

Description:

Oral TSX-002 120 mg BID for 15 days

Treatment:

Drug: TSX-002